BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 18449203)

  • 1. In-vivo detectable antibodies directed against the oncofetal antigen/immature laminin receptor can recognize and control myeloma cells--clinical implications.
    Siegel S; Friedrichs B; Budde AK; Barsoum A; Coggin J; Tiemann M; Kabelitz D; Zeis M
    Leukemia; 2008 Nov; 22(11):2115-8. PubMed ID: 18449203
    [No Abstract]   [Full Text] [Related]  

  • 2. Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vbeta repertoire.
    Pérez-Andres M; Almeida J; Martin-Ayuso M; Moro MJ; Martin-Nuñez G; Galende J; Hernandez J; Mateo G; San Miguel JF; Orfao A; ;
    Cancer; 2006 Mar; 106(6):1296-305. PubMed ID: 16475149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q.
    Mitsiades CS
    Haematologica; 2005 Apr; 90(4):436-7. PubMed ID: 15820931
    [No Abstract]   [Full Text] [Related]  

  • 4. CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q.
    Liebisch P; Eppinger S; Schöpflin C; Stehle G; Munzert G; Döhner H; Schmid M
    Haematologica; 2005 Apr; 90(4):489-93. PubMed ID: 15820944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Production, safety and antitumor efficacy of recombinant Oncofetal Antigen/immature laminin receptor protein.
    Barsoum AL; Liu B; Rohrer JW; Coggin JH; Tucker JA; Pannell LK; Schwarzenberger PO
    Biomaterials; 2009 Jun; 30(17):3091-9. PubMed ID: 19268360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral immune responses against the immature laminin receptor protein show prognostic significance in patients with chronic lymphocytic leukemia.
    Friedrichs B; Siegel S; Kloess M; Barsoum A; Coggin J; Rohrer J; Jakob I; Tiemann M; Heidorn K; Schulte C; Kabelitz D; Steinmann J; Schmitz N; Zeis M
    J Immunol; 2008 May; 180(9):6374-84. PubMed ID: 18424761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment.
    Pérez-Andrés M; Almeida J; Martín-Ayuso M; Moro MJ; Martín-Nuñez G; Galende J; Borrego D; Rodríguez MJ; Ortega F; Hernandez J; Moreno I; Domínguez M; Mateo G; San Miguel JF; Orfao A; ;
    Leukemia; 2005 Mar; 19(3):449-55. PubMed ID: 15674420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgE-type multiple myeloma with the late development of IgA2 kappa and plasma cell leukaemia.
    Chiu W; Pullon H; Woon ST; Oei P; The R; Ameratunga R
    Pathology; 2010 Jan; 42(1):82-4. PubMed ID: 20025486
    [No Abstract]   [Full Text] [Related]  

  • 9. Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines.
    Maura F; Petljak M; Lionetti M; Cifola I; Liang W; Pinatel E; Alexandrov LB; Fullam A; Martincorena I; Dawson KJ; Angelopoulos N; Samur MK; Szalat R; Zamora J; Tarpey P; Davies H; Corradini P; Anderson KC; Minvielle S; Neri A; Avet-Loiseau H; Keats J; Campbell PJ; Munshi NC; Bolli N
    Leukemia; 2018 Apr; 32(4):1044-1048. PubMed ID: 29209044
    [No Abstract]   [Full Text] [Related]  

  • 10. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma.
    Paiva B; Pérez-Andrés M; Vídriales MB; Almeida J; de las Heras N; Mateos MV; López-Corral L; Gutiérrez NC; Blanco J; Oriol A; Hernández MT; de Arriba F; de Coca AG; Terol MJ; de la Rubia J; González Y; Martín A; Sureda A; Schmidt-Hieber M; Schmitz A; Johnsen HE; Lahuerta JJ; Bladé J; San-Miguel JF; Orfao A; ;
    Leukemia; 2011 Apr; 25(4):697-706. PubMed ID: 21252988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncofetal antigen/immature laminin receptor protein in pregnancy and cancer.
    Barsoum AL; Schwarzenberger PO
    Cell Mol Biol Lett; 2014 Sep; 19(3):393-406. PubMed ID: 25082063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunologic basis for the rare occurrence of true nonsecretory plasma cell dyscrasias.
    Decourt C; Galea HR; Sirac C; Cogné M
    J Leukoc Biol; 2004 Sep; 76(3):528-36. PubMed ID: 15155772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies specific for oncofetal antigen--immature laminin receptor protein: Effects on tumor growth and spread in two murine models.
    McClintock SD; Warner RL; Ali S; Chekuri A; Dame MK; Attili D; Knibbs RK; Aslam MN; Sinkule J; Morgan AC; Barsoum A; Smith LB; Beer DG; Johnson KJ; Varani J
    Cancer Biol Ther; 2015; 16(5):724-32. PubMed ID: 25799942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction between clonal plasma cells and the immune system in plasma cell dyscrasias.
    Perez-Andres M; Almeida J; Martin-Ayuso M; Moro MJ; Garcia-Marcos MA; Moreno I; Dominguez M; Galende J; Heras N; Gonzalez MI; San Miguel JF; Orfao A;
    J Biol Regul Homeost Agents; 2004; 18(2):161-5. PubMed ID: 15471221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma.
    Bacher U; Haferlach T; Kern W; Alpermann T; Schnittger S; Haferlach C
    Cancer Genet Cytogenet; 2010 Dec; 203(2):169-75. PubMed ID: 21156229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia.
    Rasillo A; Tabernero MD; Sánchez ML; Pérez de Andrés M; Martín Ayuso M; Hernández J; Moro MJ; Fernández-Calvo J; Sayagués JM; Bortoluci A; San Miguel JF; Orfao A
    Cancer; 2003 Feb; 97(3):601-9. PubMed ID: 12548602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two cases of plasma cell leukemia with atypical immunophenotype.
    Buda G; Carulli G; Orciuolo E; Cannizzo E; Zucca A; Azzarà A; Rossi A; Galimberti S; Cecconi N; Petrini M
    Acta Haematol; 2007; 118(1):27-9. PubMed ID: 17429194
    [No Abstract]   [Full Text] [Related]  

  • 18. Disruption of INK4/CDK/Rb cell cycle pathway by gene hypermethylation in multiple myeloma and MGUS.
    Chim CS; Fung TK; Liang R
    Leukemia; 2003 Dec; 17(12):2533-5. PubMed ID: 12970764
    [No Abstract]   [Full Text] [Related]  

  • 19. Cancer specific Mucin-1 glycoforms are expressed on multiple myeloma.
    Cloosen S; Gratama J; van Leeuwen EB; Senden-Gijsbers BL; Oving EB; von Mensdorff-Pouilly S; Tarp MA; Mandel U; Clausen H; Germeraad WT; Bos GM
    Br J Haematol; 2006 Nov; 135(4):513-6. PubMed ID: 17010104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunopathology of paraproteinemic hemoblastoses].
    Huber H; Gattringer C; Peer L
    Acta Med Austriaca; 1982; 9(4):135-8. PubMed ID: 6982580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.